Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
50 results about "Heparin coating" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Heparin coatings work by preventing platelet adhesion and activation, events that must be minimized to maintain blood compatibility. Heparin is a highly charged molecule that interferes with the blood-clotting mechanisms by catalyzing the inactivation of enzymessuch as thrombin and Factor X ain the fibrin cascade.
The invention includes a medical hydrogel made from polymerized polysaccharide macromers. The macromers are preferably polysaccharides decorated with polymerizable groups, for example, methacrylates. The macromers may also be made into polymers of at least two macromers polymerized together. These polymers are preferably multi-armed or high-molecular weight and used for medical uses, for example, making coatings on medical devices. Macromers of N-vinylpyrrolidone are also disclosed herein.
The invention relates to a small-caliber artificial blood vessel with the surface grafted with a heparincoating and a preparation method of the small-caliber artificial blood vessel. A small-caliberblood vessel is adopted as a substrate. The preparation method comprises the following steps: soaking the surface of the substrate in a dopamine solution for reaction, coating the surface of the substrate with multiple layers of polydopamine coatings, performing chemical bond combination grafting with polyethyleneimine, and finally activating heparin by utilizing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and N-hydroxysuccinimide (NHS) to obtain the heparinized surface through amido bond combination. The invention has the characteristics of small caliber, favorable mechanical properties, hydrophilicity and long-acting anticoagulation; the preparation method is environmentally friendly and efficient in compounding, the prepared heparincoating is uniform, the grafting amount of heparin is higher and can reach 4.9 mu g / cm < 2 >, and good market application prospects are achieved.
The invention discloses an anticoagulantcoating. The anticoagulantcoating sequentially comprises a base material, a polydopamine coating, a multi-amino compound connecting layer and a heparin-protein functional layer from bottom to top, and all the layers are connected through covalent bonds. According to the anticoagulant coating, heparin molecules are modified through protein, and the problem that an existing covalent bonding method heparin coating is poor in anticoagulant effect is solved; a bottom layer and a functional layer are connected through a connecting layer, so the problem that an existing coating is poor in blood stability is solved; and a solution flowing method is used for coating a polydopamine base coat, and the problem that an existing dip-coating method is not uniform in coating is solved. Meanwhile, the invention further discloses a preparation method of the anticoagulant coating. The preparation process of the anticoagulant coating is simple to operate, the whole coating time can be controlled within 8 hours, and the anticoagulant coating has good application potential.
The invention provides a method for single-step terminal sterilization process for bio-active heparin coatings on materials and biomaterials containing heparin used in medical devices, such as catheters, tissue engineering scaffolds, or drug delivery carrier materials. This may include any medical device or implantable that could benefit from improved antithrombotic and biocompatible heparin surfaces. Other relevant device examples may include heparin or a heparin derivative coated stents to reduce clotting and restenosis, dental or ophthalmological implants. These materials may comprise additional polymeric compositions such as polyethyleneimine, dextransulfate or their modified forms. These polymers together with heparin coatings may be applied to other substrate of medical devices such as metal, ceramics or biologically derived materials.
The invention includes a medical hydrogel made from polymerized polysaccharide macromers. The macromers are preferably polysaccharides decorated with polymerizable groups, for example, methacrylates. The macromers may also be made into polymers of at least two macromers polymerized together. These polymers are preferably multi-armed or high-molecular weight and used for medical uses, for example, making coatings on medical devices. Macromers of N-vinylpyrrolidone are also disclosed herein.
The invention relates to a modified polymeric membrane material and a preparation method thereof. The modified polymeric membrane material is mainly characterized in that the surface of the polymeric membrane material is grafted with two coatings having a substance with anticoagulant action, namely a phosphorylcholinezwitterioncoating and a heparincoating. The preparation method of the coating comprises the following steps: step 1, grafting the surface of the polymeric membrane material with phosphorylcholine and acrylamidecopolymer; step 2, putting the treated polymeric membrane material into a cleaning solution for cleaning, soaking and drying; and step 3, reacting residual amino groups grafted on the polymeric membrane material dried in step 2 with a EDC and NHS-activated heparin solution obtain the modified polymeric membrane material with the surface compounded and grafted with the phosphorylcholinezwitterion coating and the heparin coating. The preparation method can prepare the modified polymeric membrane material which is good in mechanical property, good in hydrophilicity and long-acting in anticoagulation. The prepared heparin coating is uniform, the heparin grafting amount is high and can reach 6.3 [mu]g / cm<2>, and the heparin coating has a good market prospect.
The invention provides an alkene-functionalized heparin compound and application thereof. According to the invention, an isocyanate group of an unsaturated monomer with an isocyanate group reacts witha hydroxyl group in heparin to obtain the alkene-functionalized heparin compound; and the alkene-functionalized heparin compound can be obtained under mild reaction conditions and does not influencethe activity of the heparin. Meanwhile, the alkene-functionalized heparin compound is mixed with a photoinitiator, a solvent and the like to form a heparin coating solution, alkene functional groups participate in a photo-initiated free radical polymerization reaction to form a cross-linked skeleton, and heparin molecules are arranged on the surface of the cross-linked skeleton, so a heparin coating obtained by using the method does not need the surface of a substrate material to have a special structure or special performance and does not need complex pretreatment; and the application range of the material is wide, and a process is simple.
The invention belongs to the technical field of medical instruments, and particularly relates to an axial flow type heart-assist apparatus with a heparincoating and hydrophobic protection. The heart-assist apparatus comprises a blood flow channel, an axial flow impeller and a driving motor, wherein the driving motor comprises a stator shell which is integrally cylindrical, the stator shell is provided with an accommodating space for arranging a columnar rotor, rotating shafts are arranged at two ends of the columnar rotor, bearings are arranged between shaft bodies at two ends of the rotatingshafts and two ends of the stator shell, and heparin is attached to the surface of the stator shell and the surface of the columnar rotor. According to the heart-assist apparatus, heparin is attachedto the adjacent surfaces of the columnar rotor and the stator shell, so that the thrombus formation is effectively inhibited; and meanwhile, a hydrophobic material is attached to the inner surface ofthe bearing close to a blood outflow opening, and the shaft body of the corresponding rotating shaft, so that blood is effectively prevented from entering the inside of the driving motor.
The invention relates to a membrane-type oxygen exchange device. The membrane-type oxygen exchange device is used for removing carbon dioxide in blood and enriching oxygen in the blood, and comprises a hexahedron housing and a core mounted in the housing, wherein the bottom and the corresponding top of the hexahedron housing are provided with a venous blood inlet and an arterial blood outlet respectively, and a set of opposite sides of the hexahedron housing are provided with an oxygen inlet and a carbon dioxide outlet respectively; the core is a hollow semipermeable membranefiber bundle formed by a plurality of semipermeable membranes, and one end of each semipermeable membrane is communicated with the oxygen inlet while the other end of each semipermeable membrane is communicated with the carbon dioxide outlet; the outer surface of each semipermeable membrane is coated with a heparincoating, and the blood enters the housing through the venous blood inlet, and undergoes blood oxygen exchange with oxygen which enters the semipermeable membranes from the oxygen inlet; produced carbon dioxide is discharged from the carbon dioxide outlet, and the blood which completes the blood oxygen exchange is discharged from the arterial blood outlet. According to the membrane-type oxygen exchange device, the formation of thrombus in the blood can be effectively inhibited, and the gas exchange efficiency is improved.
The invention relates to a vascular covered stent with a novel-type coating in the field of peripheral blood vessels. The stent consists of an inner surface tectorial membrane, a metalstent, an outersurface tectorial membrane and a development structure, a parylenecoating is coated on the surface of the metalstent, the head end of a product is processed into a petal-shaped structure, and heparin coatings are coated on the surfaces of the inner surface tectorial membrane and the outer surface tectorial membrane. The petal-shaped structure at the head end of the product can reduce stimulation of the head end of the product to the inner wall of a blood vessel at a contact part, so as to prevent marginal stenosis of the head end of the stent. The metal stent is coated with parylene to forma protective layer, so that the metal stent can be prevented from being corroded by blood, stent metal ions are prevented from entering human bodies and harming the health of patients, the smoothnessof the parylenecoating can improve the pushing performance of a product when the product is conveyed, and the heparin coating on the surface of the tectorial membrane can prevent thrombosis at the contact part of the product and further prevent restenosis of blood vessels.
A process for preparing a coated heparin layer on the surface of medical equipment, where the blood is contacted features that a polyvinylimine method is used to make said surface carry the free amino space structure and positive charges for ion-bond binding with the negative charges of heparin moleculae or a cross-linking agent is used for co-valence bond binding with aminos in heparin moleculae to fix the heparin molecular onto said surface. Its advantages are high bioactivity, biological combatibility and anti-coagulating activity, and low toxic by-effect.
Owner:NO 1 AUXILARY HOSPITAL NO 4 MILLITARY MEDICAL UNIV P L A +1
The invention belongs to the technical field of medical appliances, and discloses a capped tube core of a deep vein infusion tube with a heparincoating for one-time use, which is provided with a heparin cap; Inserted into the deep vein infusion tube, the tip of the core is soft and blunt, and the tail is made of a slightly tougher material. The length of the core is slightly longer than the length of the deep vein infusion tube. After each infusion, use iodophor to repeatedly disinfect the outer port of the CVC, insert the tube core from the external port with sterile gloves, and then rotate the screw cap at the end of the tube core to tightly seal the external port of the infusion tube. When using it for the first time, turn the screw cap to pull it out, and then connect the infusion tube for infusion after the empty needle is drawn back to see fresh blood. The invention can effectively avoid the thrombus formation near the inner mouth of the catheter caused by long-term catheterization, resulting in CVC blockage, and the patency of the CVC is crucial to the survival of patients.
The embodiment of the invention discloses a thrombolytic catheter device. The thrombolytic catheter device comprises an inner sleeve, an outer sleeve sleeving the inner sleeve, and a base for fixing the outer sleeve and the inner sleeve; a perfusion cavity is formed between the outer sleeve and the inner sleeve, a plurality of perfusion holes are formed in the far end of the outer sleeve, and a perfusion port communicated with the perfusion holes and an inlet of the inner sleeve are formed in the base; the perfusion cavity and an inner cavity of the inner sleeve are mutually independent and are not communicated with each other. According to the thrombolytic catheter device, on the one hand, the perfusion holes are formed in the far end of the outer sleeve, so that the thrombolytic efficiency is improved; on the other hand, the outer wall of the outer sleeve is covered with a heparincoating and the portion close to the base is coated with a hydrophilic coating, so that in the use process, thrombi are prevented from forming around a catheter, and the thrombolytic effect and the thrombolytic efficiency are improved.
The invention discloses a minimally invasive upper and lower vena cava and coronary sinusdrainage catheter, which comprises a vein drainage pipeline with a heparincoating and a coronary sinus blocking balloon; side holes of two areas are formed in the vein drainage pipeline; furthermore, the side holes of the two areas are located in the mirror surface position of an upper cavity and the mirror surface position of a lower cavity respectively to achieve the effect of fully draining blood; the vein drainage pipeline located in the upper vena cava position and the vein drainage pipeline located in the lower vena cava position are sleeved with an upper cavity blocking balloon and a lower cavity blocking balloon respectively; the vein drainage pipeline located in the middle of an upper vena cava blocking balloon and a lower vena cava blocking balloon is connected with a side pipe; the side pipe is sleeved with the coronary sinus blocking balloon; the upper cavity blocking balloon, the lower cavity blocking balloon and the coronary sinus blocking balloon are all connected with one-way valves to achieve inflation of injected gas; and the minimally invasive upper and lower vena cava and coronary sinus drainage catheter has the following technical features that: the number of intubations and the time of suture separation can be reduced; additional exploration and hemostasis are not needed; the operation space and efficiency are effectively increased; and the clear view can be ensured.
The invention relates to the technical field of ophthalmic medical biological materials, and provides an artificial aqueous humor micro-drainage tube with drug sustained-release function and a preparation method. Design and femtosecondlaser technology, make holes on the drug-loaded microdrainage tube substrate, and covalently graft heparincoating on the surface of the substrate through graftingcoupling technology, which is suitable for minimally invasive implantation, not only has good biocompatibility, It has high safety, and has good flexibility and compliance. The arrayed microporous structure of the tube wall can effectively conduct aqueous humor flow, while avoiding the failure of the device due to channel blockage, and the heparincoating on its surface can effectively prevent tissue fluid or blood. A scar or thrombus is formed on its surface, and the micro-drainage tube is loaded with therapeutic drugs, which can inhibit inflammation, allergy, immunity and other reactions of surrounding tissues after slow release.